Literature DB >> 20473786

Using telcagepant for the acute treatment of migraine.

Frederick R Taylor1.   

Abstract

Entities:  

Year:  2010        PMID： 20473786     DOI： 10.1007/s11916-010-0113-y

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


× No keyword cloud information.
  14 in total

Review 1.  Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine.

Authors:  Stewart J Tepper; Mark J Stillman
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

2.  Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack.

Authors:  G Juhasz; T Zsombok; B Jakab; J Nemeth; J Szolcsanyi; G Bagdy
Journal:  Cephalalgia       Date:  2005-03       Impact factor: 6.292

3.  Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.

Authors:  Stewart J Tepper; Catalina Cleves
Journal:  Curr Opin Investig Drugs       Date:  2009-07

4.  Acute myocardial infarction with sumatriptan: a case report and review of the literature.

Authors:  Flavio Devetag Chalaupka
Journal:  Headache       Date:  2009-05       Impact factor: 5.887

5.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

6.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

7.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

Review 8.  The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.

Authors:  Carlos M Villalón; Jes Olesen
Journal:  Pharmacol Ther       Date:  2009-09-29       Impact factor: 12.310

9.  Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.

Authors:  Joseph J Lynch; Christopher P Regan; Lars Edvinsson; Richard J Hargreaves; Stefanie A Kane
Journal:  J Cardiovasc Pharmacol       Date:  2010-05       Impact factor: 3.105

10.  Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.

Authors:  Peer C Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-09-25       Impact factor: 7.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.